Catalyst Brief

← Calendar

Readoutin 13d

Pfizer — Ritlecitinib higher dose

Phase 3 primary completion: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata.

Date
Dec 2026
Type
Readout
Indication
Severe Alopecia Areata

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Pfizer

  1. Apr2027
  2. Feb2027
    Readoutin 75d
    Pfizer — PF-06821497
    Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)..
  3. Jan2027